PepGen: Best-in-Class DM1 Data Reopens a Race Novartis Just Fumbled

PepGen is a clinical-stage biotechnology company built on its Enhanced Delivery Oligonucleotide (EDO) platform: proprietary cell-penetrating peptides conjugated to antisense oligonucleotides to improve cellular uptake and nuclear delivery into muscle tissue — historically the core problem for RNA drugs in neuromuscular disease. The company generates no product revenue today; it is funded by equity markets and spends on a single advancing clinical franchise.

Its lead candidate, PGN-EDODM1, is an EDO peptide-conjugated PMO administered as a monthly intravenous infusion. It selectively binds expanded CUG repeats in pathogenic DMPK RNA, releasing MBNL1 — a key splicing regulator sequestered by the toxic RNA — thereby correcting the mis-splicing that drives DM1. Unlike RNA-degrading approaches, it is designed to disrupt pathogenic hairpin structures while preserving normal DMPK function. The FDA has granted Orphan Drug and Fast Track designations; the EMA granted Orphan designation; and in October 2026 the FDA selected the program for its CMC Development and Readiness Pilot ahead of Phase 3 planning.

Founded in 2018 as a University of Oxford spinout and headquartered in Boston with roughly 57 employees, PepGen runs the multinational FREEDOM2 Phase 2 (Canada, UK, New Zealand, Australia, South Korea) and the FREEDOM open-label extension, which together have now delivered more than 135 doses across the program. The commercial model, if approved, is classic orphan-drug economics: a 110,000+ patient US/EU prevalence with multi-systemic, lifelong disease supports premium pricing for the first disease-modifying therapy, with monthly infused dosing creating a durable, recurring revenue base.

Q3 2026 vs Q3 2025 (Three Months Ended September 30)

Quarterly Progression

Full-Year Results

Nine-month 2026 cash consumption of $43.7 million (from $148.5 million at year-end) annualizes to ≈$58 million — consistent with management's runway-into-2028 guidance without an interim raise, though a pivotal-scale program would likely require new capital.

Balance Sheet Snapshot (September 30, 2026)

Outlook: No revenue; management states cash funds operations into 2028. Milestones: FREEDOM-OLE interim safety (10 mg/kg) and clinical (5 mg/kg) data January 2027; FREEDOM2 12.5 mg/kg results 1H 2027; end-of-Phase 2 meeting 2H 2027 pending removal of the partial clinical hold.

DM1 drug development is a graveyard: Ionis and Biogen's antisense partnership failed in Phase 1/2 back in 2015; Faze, Triplet, and Expansion Therapeutics all shut down; Arrowhead outlicensed its program to Sarepta; Fulcrum suspended its repeat-expansion program in 2024. That history makes PepGen's placebo-controlled functional data genuinely differentiated — most of the field never survived long enough to generate any.

• Novartis (NVS) / Avidity — del-desiran: The $12 billion acquisition was the field's marquee bet, but the Phase 3 HARBOR study missed its primary vHOT endpoint in September 2026, resetting expectations for the whole space. Antibody-oligonucleotide conjugate, siRNA mechanism targeting DMPK.

• Dyne Therapeutics (DYN) — z-basivarsen (DYNE-101): The acknowledged pipeline leader, running HARMONIA — the only Phase 3 DM1 trial currently enrolling participants. Antibody-fragment conjugated antisense with reported Phase 1/2 gains in strength and cognition. Dyne's readout will define how much room is left for PepGen.

• Vertex (VRTX) — VX-670: A peptide-conjugated oligonucleotide targeting DMPK, in-licensed from Entrada in 2023 — the same modality class as PepGen's EDO. Earlier stage, but backed by Vertex's balance sheet and muscle-disease franchise ambitions.

• AMO Pharma — tideglusib: Small-molecule GSK3-beta inhibitor focused on congenital and juvenile DM1, a niche within the niche.

• Symptomatic standard of care: Mexiletine (sodium channels) and pitolisant (H3R) manage myotonia and daytime sleepiness but do not modify disease — the backdrop that makes any disease-modifying approval a step-change.

Moats:

1. Highest reported multi-dose splicing correction in DM1 (46.5% vs 6.8% placebo)
2. Only program demonstrating a large placebo-controlled vHOT improvement after HARBOR's failure on that exact endpoint
3. EDO peptide delivery with demonstrated nuclear muscle uptake at low monthly doses
4. US Orphan Drug and Fast Track plus EMA Orphan designation, and FDA CMC pilot selection
5. Mechanism preserves normal DMPK function, avoiding knockdown-related safety questions

1. FREEDOM-OLE interim data — January 2027: 10 mg/kg safety and 5 mg/kg clinical data from the open-label extension; 19 participants enrolled, over 135 doses administered to date

2. FREEDOM2 12.5 mg/kg topline — 1H 2027: The highest-dose cohort is fully enrolled with up to three doses delivered; a clean dose-response would fully de-rate the bear case

3. Partial clinical hold resolution: The March 2026 FDA hold (nonclinical mouse findings) blocks US dosing; resolution unlocks the planned 2H 2027 end-of-Phase 2 meeting and a US pivotal pathway, and the company is already running the nonclinical mouse studies FDA requested

4. Expansion cohort with 9-month dosing data: Planned to run in parallel with Cohort 3, extending durability evidence beyond the current 16-week observation window and supporting label-breadth arguments across myotonia, strength, and mobility

5. Strategic interest: Novartis' $12 billion Avidity deal proves pharma will pay up for DM1 assets; a validated PepGen becomes one of only two credible takeover targets in the entire indication, and the CDRP manufacturing pilot signals FDA engagement that acquirers would inherit